Uveal melanoma (UM) is a common type of adult ocular malignancy, and its metastasis potential and prognosis are closely related to tumor stage, histopathological features and genetic molecular markers. Currently, eyeball-preserving radiation therapy, including adhesive radiotherapy and proton beam radiotherapy, has become the preferred method for UM treatment. Despite this, overall survival is low, with about 50% of patients eventually developing distant metastases. Recently, remarkable progress has been made in the field of treatment for metastatic uveal melanoma, especially in the development of new technologies and new drugs. These advances reduce the risk of tumor metastasis and spread while improving the cure rate for patients. Tibenfox is a major breakthrough in the treatment of UM. Through these explorations, it is hoped that in the future, early diagnosis of the disease can guide prognosis assessment and implement personalized treatment strategies aimed at protecting patient vision, controlling tumor metastasis, and improving survival.
